Skip to main content

Allscripts Healthcare Solution Value Stock - Dividend - Research Selection

Allscripts healthcare solution

ISIN: US01988P1084 , WKN: 607917

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Allscripts Healthcare Solutions, Inc. provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions. The company\'s Clinical and Financial Solutions segment provides integrated clinical software applications and financial and information solutions, which primarily include EHR-related, and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training, and electronic claims administration services. Its Population Health segment offers health management and coordinated care solutions that enable hospitals, health systems, accountable care organizations, and other care facilities to connect, transition, analyze, and coordinate care across the entire care community. The company\'s Netsmart segment operates in and provides software and technology solutions to the health and human services, and post-acute sectors of health care. The company serves physicians, hospitals, governments, health systems, health plans, life-sciences companies, retail clinics, retail pharmacies, pharmacy benefit managers, insurance companies, and employer wellness clinics, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Veradigm Network Solution Practice Fusion EHR Receives Top Ranking

2023-03-23
CHICAGO, March 23, 2023--Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Practice Fusion first for Allergy and Immunology and second for Rheumatology within its 2023 Ambulatory EHR by Physician Specialty category.

Analysts` Top Technology Picks: Allscripts (MDRX), Sony Group (SONY)

2023-03-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Veradigm cuts revenue forecast for fiscal 2023

2023-03-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing, Provides Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results

2023-03-22
CHICAGO, March 22, 2023--Veradigm Inc. (NASDAQ: MDRX), announced today an update on the status of its year-end audit procedures for 2022. As the Company disclosed on February 28, 2023, due to an expansion of year-end audit procedures, the Company filed with the SEC a Form 12b-25, extending the due date of its annual report on Form 10-K by 15 days, to allow for completion of those procedures.

Veradigm affirms FY23 EPS view of 80c-90c, consensus 90c

2023-03-22
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Despite shrinking by US$50m in the past week, Veradigm (NASDAQ:MDRX) shareholders are still up 139% over 3 years

2023-03-20
Veradigm Inc. ( NASDAQ:MDRX ) shareholders might be concerned after seeing the share price drop 26% in the last...

Veradigm Practice Management Ranks First in Practice Management Solutions from Black Book™ Research

2023-03-14
CHICAGO, March 14, 2023--Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Veradigm Practice Management first for its 2023 Practice Management Solutions, 50+ Physician Groups category.

Veradigm price target lowered to $17 from $24 at SVB Securities

2023-03-01
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Veradigm Inc. Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results

2023-02-28
CHICAGO, February 28, 2023--Veradigm Inc. (NASDAQ: MDRX), announced today that in conjunction with its year-end audit procedures it has detected certain internal control failures related to revenue recognition that have occurred over the prior six quarters, resulting in a mis-statement to reported revenues during those periods. As a result, the Company and its external auditors need to expand procedures and are filing with the SEC a Form 12b-25, extending the due date of the Company’s Form 10-K

Veradigm Down 5% After Hours, Reports Internal Control Failures

2023-02-28
By Josh Beckerman Veradigm Inc. shares fell 5% to $15.81 after hours as the company said it will restate financial results and delayed an earnings call...